# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Affimed (NASDAQ:AFMD) from Buy to Neutral.
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to ...
Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:AFMD) from Overweight to Equal-Weight and lowers the price target f...